secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001558370-23-014849
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio Q2 net loss $16.2M; completes uBriGene asset sale for $6M
---------------------------------------------------------------------

- Cash and equivalents $16.1M at June 30, down from $76.7M at Dec 31, 2022, reflecting Runway loan repayment.
- Net loss $16.2M ($2.00/share) vs $19.1M ($2.50/share) in Q2 2022.
- Closed amended asset sale to uBriGene for $6M upfront; expects $28M annual cost reduction.
- Lead CAR T MB-106 shows 83% response in WM cohort; 95% ORR in FL cohort.
- First pivotal Phase 2 WM patient expected Q1 2024; additional multicenter data in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023014849/0001558370-23-014849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023014849/tmb-20230814x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer